Logo image of ZBIO

ZENAS BIOPHARMA INC (ZBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZBIO - US98937L1052 - Common Stock

35.8 USD
+0.96 (+2.76%)
Last: 11/21/2025, 8:06:41 PM
35.8 USD
0 (0%)
After Hours: 11/21/2025, 8:06:41 PM
Fundamental Rating

2

Taking everything into account, ZBIO scores 2 out of 10 in our fundamental rating. ZBIO was compared to 535 industry peers in the Biotechnology industry. The financial health of ZBIO is average, but there are quite some concerns on its profitability. ZBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZBIO has reported negative net income.
ZBIO had a negative operating cash flow in the past year.
ZBIO Yearly Net Income VS EBIT VS OCF VS FCFZBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ZBIO's Return On Assets of -58.97% is in line compared to the rest of the industry. ZBIO outperforms 43.18% of its industry peers.
With a Return On Equity value of -96.68%, ZBIO perfoms like the industry average, outperforming 48.97% of the companies in the same industry.
Industry RankSector Rank
ROA -58.97%
ROE -96.68%
ROIC N/A
ROA(3y)-85.61%
ROA(5y)N/A
ROE(3y)-150.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZBIO Yearly ROA, ROE, ROICZBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZBIO Yearly Profit, Operating, Gross MarginsZBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

ZBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZBIO has been increased compared to 1 year ago.
ZBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZBIO Yearly Shares OutstandingZBIO Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
ZBIO Yearly Total Debt VS Total AssetsZBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

ZBIO has an Altman-Z score of 4.73. This indicates that ZBIO is financially healthy and has little risk of bankruptcy at the moment.
ZBIO has a Altman-Z score of 4.73. This is in the better half of the industry: ZBIO outperforms 74.58% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that ZBIO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.37, ZBIO is not doing good in the industry: 70.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 4.73
ROIC/WACCN/A
WACC8.67%
ZBIO Yearly LT Debt VS Equity VS FCFZBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ZBIO has a Current Ratio of 5.66. This indicates that ZBIO is financially healthy and has no problem in meeting its short term obligations.
ZBIO's Current ratio of 5.66 is fine compared to the rest of the industry. ZBIO outperforms 60.19% of its industry peers.
A Quick Ratio of 5.66 indicates that ZBIO has no problem at all paying its short term obligations.
ZBIO's Quick ratio of 5.66 is fine compared to the rest of the industry. ZBIO outperforms 61.87% of its industry peers.
Industry RankSector Rank
Current Ratio 5.66
Quick Ratio 5.66
ZBIO Yearly Current Assets VS Current LiabilitesZBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ZBIO have decreased strongly by -296.61% in the last year.
ZBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -90.00%.
EPS 1Y (TTM)-296.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.7%
Revenue 1Y (TTM)-90%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.39% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y48.05%
EPS Next 2Y16.4%
EPS Next 3Y12.81%
EPS Next 5Y10.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZBIO Yearly Revenue VS EstimatesZBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ZBIO Yearly EPS VS EstimatesZBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZBIO Price Earnings VS Forward Price EarningsZBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZBIO Per share dataZBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

ZBIO's earnings are expected to grow with 12.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.4%
EPS Next 3Y12.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENAS BIOPHARMA INC

NASDAQ:ZBIO (11/21/2025, 8:06:41 PM)

After market: 35.8 0 (0%)

35.8

+0.96 (+2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-09 2026-03-09
Inst Owners78.01%
Inst Owner Change2.11%
Ins Owners0.8%
Ins Owner Change0.2%
Market Cap1.69B
Revenue(TTM)15.00M
Net Income(TTM)-189.90M
Analysts89.23
Price Target44.44 (24.13%)
Short Float %14.43%
Short Ratio10.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.44%
Min EPS beat(2)-16.71%
Max EPS beat(2)-14.17%
EPS beat(4)1
Avg EPS beat(4)-73.08%
Min EPS beat(4)-290.79%
Max EPS beat(4)29.34%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)34.36%
PT rev (3m)37.39%
EPS NQ rev (1m)45.59%
EPS NQ rev (3m)48.84%
EPS NY rev (1m)9.69%
EPS NY rev (3m)14.95%
Revenue NQ rev (1m)375%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)53.57%
Revenue NY rev (3m)258.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 112.44
P/FCF N/A
P/OCF N/A
P/B 8.59
P/tB 8.59
EV/EBITDA N/A
EPS(TTM)-7.26
EYN/A
EPS(NY)-4.82
Fwd EYN/A
FCF(TTM)-3.47
FCFYN/A
OCF(TTM)-3.36
OCFYN/A
SpS0.32
BVpS4.17
TBVpS4.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.97%
ROE -96.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.61%
ROA(5y)N/A
ROE(3y)-150.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6445.57%
Cap/Sales 33.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.66
Quick Ratio 5.66
Altman-Z 4.73
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)976.2%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-296.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.7%
EPS Next Y48.05%
EPS Next 2Y16.4%
EPS Next 3Y12.81%
EPS Next 5Y10.39%
Revenue 1Y (TTM)-90%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-35.82%
EBIT Next 3Y-25.07%
EBIT Next 5YN/A
FCF growth 1Y-390.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-391.3%
OCF growth 3YN/A
OCF growth 5YN/A

ZENAS BIOPHARMA INC / ZBIO FAQ

What is the fundamental rating for ZBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to ZBIO.


Can you provide the valuation status for ZENAS BIOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to ZENAS BIOPHARMA INC (ZBIO). This can be considered as Overvalued.


Can you provide the profitability details for ZENAS BIOPHARMA INC?

ZENAS BIOPHARMA INC (ZBIO) has a profitability rating of 1 / 10.


What is the financial health of ZENAS BIOPHARMA INC (ZBIO) stock?

The financial health rating of ZENAS BIOPHARMA INC (ZBIO) is 7 / 10.